Rita Nanda, MD
Enriched profileAssociate Professor of Medicine; Director, Breast Oncology Program · University of Chicago
Rita Nanda is Associate Professor of Medicine; Director, Breast Oncology Program at University of Chicago. OpenAlex indexes 548 publications with 17,578 citations (h-index 57); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Rita Nanda is Associate Professor of Medicine at University of Chicago. The public record shows 548 publications with 17,578 citations (h-index 57), centered on Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 16 companies, 1 NIH-funded awards (2018–2020).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Breast Cancer Treatment Studies
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 42 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 151.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
Sponsor: University of Chicago
- A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Sponsor: SWOG Cancer Research Network
Industry payments
Updated 27 Aug 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202512 payments$14,952openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year202513 payments
- PFIZER INC.Program year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
90.7%Aromatase Inhibitor49.6%Exemestane41%Anastrozole36%Letrozole23%Part D<11 patientsKinase inhibitor41.1%Ibrance53%Kisqali47%Part D<11 patientsNervous system
9.3%Gabapentinoids9.3%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2018–2020 per NIH RePORTER. The latest:
- UChicago Interdisciplinary Cancer Health Disparities SPORE
University of Chicago
FY2020$1,075,670P20CA233307 - UChicago Interdisciplinary Cancer Health Disparities SPORE
University of Chicago
FY2020$162,000P20CA233307 - UChicago Interdisciplinary Cancer Health Disparities SPORE
University of Chicago
FY2019$1,043,400P20CA233307
Congress activity
Updated 27 Aug 2026
196 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 1310: Targeting pro-metastatic stress networks in triple-negative breast cancer using patient-derived models
AACR Annual Meeting
AACR2025Co-author - Breast cancer recurrence and mortality among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.
Science translational medicine
Article2026 - Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression.
Breast cancer (Dove Medical Press)
Article2026
Most-cited works
by citation count (OpenAlex)- 01The molecular portraits of breast tumors are conserved across microarray platformsArticle1,472 citations2006
- 02Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaArticle1,079 citations2005
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/rita-nanda-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Rita-Nanda
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/RitaNandaMD
Mentions by others
where others cite or feature them- Other
bcrf.org/researchers/rita-nanda
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcrf.org ↗ - Other
onclive.com/view/dr-nanda-on-the-translational-breast-cancer-research-consortium
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →directory.uchicago.edu ↗
- MD
University of Chicago Pritzker School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lbbc.org ↗
- Trustee
Board of Trustees, Triple Negative Breast Cancer Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tnbcfoundation.org ↗ - Editorial Board Member
Breast Cancer Research and Treatment
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →link.springer.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lbbc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lbbc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lbbc.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- Contributing expert/author
CancerNetwork
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Everett Vokes, MD
University of Chicago
Ralph Weichselbaum, MD
University of Chicago
Mary Rinella, MD
University of Chicago
Hedy Kindler, MD
University of Chicago